AED Plus and Fully Automatic AED Plus
ZOLL MEDICAL CORPORATION · Decision date May 26, 2017
What did the FDA approve?
FDA approved the AED Plus and Fully Automatic AED Plus from ZOLL Medical Corporation on May 26, 2017, under PMA number P160015. The approval statement describes the devices as indicated for suspected cardiac arrest when a victim shows unconsciousness, absence of normal breathing, and absence of a pulse or signs of circulation. The statement specifies that use is intended for personnel trained in basic life support/AED, advanced life support, or a physician-authorized emergency medical response program.
For victims under 8 years of age or weighing less than 55 lbs (25 kg), the statement says the devices should be used with the ZOLL AED Plus and Fully Automatic AED Plus Pediatric Electrodes. It also states that therapy should not be delayed to determine exact age or weight. The source record does not include a supplement type or reason, and it does not describe clinical testing, comparative performance, or safety outcomes beyond the approved indication and use conditions.
FDA approval order statement
Approval for the AED Plus and Fully Automatic AED Plus. These devices are indicated for use when a suspected cardiac arrest victim has an apparent lack of circulation as indicated by:1) Unconsciousness;2) Absence of normal breathing; and3) Absence of a pulse or signs of circulationThese devices are intended for use by personnel who have been trained in their operation. Users should have received training in basic life support/AED, advanced life support or a physician-authorized emergency medical response training program.When a victim is less than 8 years of age, or weighs less than 55 lbs. (25kg), the ZOLL AED Plus and Fully Automatic AED Plus should be used with the ZOLL AED Plus and Fully Automatic AED Plus Pediatric Electrodes. Therapy should not be delayed to determine the patients exact age or weight.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- May 26, 2017
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160015
- Regulatory pathway
- Premarket approval application
- Applicant
- ZOLL MEDICAL CORPORATION
- Product code
- MKJ
- Decision code
- APPR
- Decision date
- May 26, 2017
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated external defibrillators (non-wearable).
- Applicant
- ZOLL MEDICAL CORPORATION
- Product code
- MKJ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P160015 received
Application receipt date recorded by FDA.
P160015 · FDA decision
APPR
P160015/S029 · Related supplement
AED 3 Defibrillator with Uni-Padz
Timeline entries are records held by MedtechLedger for P160015. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160015
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AED 3 Defibrillator with Uni-PadzP160015/S029 | ZOLL MEDICAL CORPORATION | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code MKJ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LIFEPAK 35 monitor/defibrillatorP160026/S076 | Physio-Control, Inc. | PMA supplement | Oct 29, 2026 | FDA |
ZOLL R Series Monitor/DefibrillatorP160022/S056 | ZOLL MEDICAL CORPORATION | PMA supplement | Oct 16, 2026 | FDA |
| ZOLL MEDICAL CORPORATION | PMA supplement | Oct 2, 2026 | FDA | |
| Physio-Control, Inc. | PMA supplement | Sep 24, 2026 | FDA | |
LIFEPAK 15 monitor/defibrillatorP160026/S073 | Physio-Control, Inc. | PMA supplement | Sep 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ZOLL MEDICAL CORPORATION
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 269 & 271 Mill Rd., Chelsmford, MA, 01824
Sources and methodology
- Original FDA record: P160015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


